<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768079</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP186</org_study_id>
    <nct_id>NCT00768079</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563</brief_title>
  <acronym>MEDI-563</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of two IV dose regimens of MEDI-563 on the proportion of
      adult subjects with asthma exacerbations who required an urgent healthcare visit for
      treatment of an acute asthma exacerbation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the effect of two IV dose regimens of MEDI-563 (0.3 and 1.0 mg/kg) on
      the proportion of adult subjects with asthma exacerbations (relapse and de novo) who required
      an urgent healthcare visit for treatment of an acute asthma exacerbation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of two IV dose regimens of MEDI-563 (0.3 and 1.0 mg/kg) on the proportion of subjects with asthma exacerbations at Week 12 in adult subjects who require an urgent healthcare visit for treatment of an acute asthma exacerbation.</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events will be summarized categorically by system organ class, preferred term,severity, and relationship to investigational product</measure>
    <time_frame>Through day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-563</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-563</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo on Study Day 0 (3mL vials filled with 1.2 mL solution of 10mM histidine, 300 mM glycine, 0.02% polysorbate 20, pH 6.0.)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-563</intervention_name>
    <description>0.3 mg/kg IV MEDI-563 on Study Day 0</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-563</intervention_name>
    <description>1.0 mg/kg IV MEDI-563 on Study Day 0</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 to 60 years at the time of the administration of
             investigational product.

          -  Written informed consent and HIPAA authorization (applies to covered entities in the
             US only) obtained from the subject/legal representative prior to performing any
             protocol-related procedures, including screening evaluations.

          -  Physician-diagnosed asthma with a duration of greater than or equal to 2 years by
             medical chart or subject report.

          -  Had an asthma exacerbation requiring urgent care in the year prior to screening.

          -  Meets NHLBI for persistent asthma in the 3 months prior to the current urgent
             healthcare visit.

          -  Current asthma exacerbation that must have lasted greater than or equal to 2 hours
             prior to arrival to the urgent healthcare setting.

          -  Requires at least 2 treatments of inhaled bronchodilators for the current asthma
             exacerbation in the urgent healthcare setting or within the emergency medical system
             (EMS)for greater than or equal to 1 hour.

          -  Shows an FEV1 or PEF of not more than 70% predicted after 1 hour of treatment of the
             current asthma exacerbation.

          -  Women of child-bearing potential, unless surgically sterile (including tubal ligation)
             and/or at least 2 years post-menopausal, must have used 2 effective methods of
             avoiding pregnancy (including oral, transdermal, or implanted contraceptives,
             intrauterine device, female condom with spermicide, diaphragm with spermicide,
             cervical cap, abstinence, use of a condom with spermicide by the sexual partner, or
             sterile sexual partner) from screening through the end of the study (Study Day 84;
             Cessation of birth control after this point should be discussed with a responsible
             physician).

          -  Men, unless surgically sterile, must likewise practice 2 effective methods of birth
             control (condom with spermicide or abstinence) and must use such precautions from
             Study Day 0 through Study Day 84.

          -  Otherwise healthy by medical history and physical examination.

          -  A chest x-ray that is normal for an asthmatic population and excludes alternative
             diagnosis per the investigation.

          -  Ability to complete the follow-up period until Study Day 168 as required by protocol.

          -  The investigator has determined that the subject is clinically stable and the FEV1, is
             greater than or equal to 30% predicted prior to receiving investigational product on
             Study Day 0.

        Exclusion Criteria:

          -  Known history of allergy or reaction to any component of the investigational product
             formulation.

          -  Acute illness other than asthma at the start of the study.

          -  Fever &gt; 38.6°C (&gt;101.5°F).

          -  Current acute asthma attack is due to aspirin-induced asthma.

          -  Current asthma episode is an anaphylactoid/anaphylactic reaction presenting with acute
             bronchospasm.

          -  Evidence of clinically significant non-respiratory active infection, including ongoing
             chronic infection.

          -  History or current prolonged diarrhea, abdominal pain, and/or blood and mucus in
             stools or have minor symptoms AND have exposure to stream or lake water, been exposed
             to someone who has a parasitic infection (like a family member), or study subject has
             traveled outside the US and/or Canada within the last year.

          -  Use of immunosuppressive medication (except oral prednisone and inhaled and topical
             corticosteroids) within 30 days before randomization into the study.

          -  Have received Xolair(TM)within 6 months before randomization into the study.

          -  Receipt of immunoglobulin or blood products within 30 days before randomization into
             the study.

          -  Receipt of any investigational drug therapy within 6 months before the first dose of
             investigational product in this study through Study Day 168.

          -  History of primary immunodeficiency.

          -  Previous medical history, or evidence, of an intercurrent illness that may compromise
             the safety of the subject in the study.

          -  History of clinically significant abnormality on ECG in the opinion of the
             investigator.

          -  Pregnancy (must have a negative serum pregnancy test prior to the first dose of
             investigational product).

          -  Breastfeeding or lactating woman.

          -  History of treatment for alcohol or drug abuse within the past year.

          -  Diagnosis of COPD by a healthcare professional.

          -  Evidence of any clinically significant systemic disease on physical examination.

          -  History of cancer except basal cell carcinoma or in situ carcinoma of the cervix
             treated with apparent success with curative therapy &gt; 1 year prior to entry or other
             malignancies treated with apparent success with curative therapy &gt; 5 years prior to
             entry.

          -  Known exposure to inhaled occupational agents or fumes with an established diagnosis
             of occupational asthma.

          -  Any condition (ie, impending ventilatory failure or hemodynamic compromise) that,in
             the opinion of the investigator, would interfere with evaluation of the
             investigational product or interpretation of study results.

          -  Any employee of the clinical study site who is involved with the conduct of the study.

          -  History of cigarette smoking &gt; 20 pack years.

          -  Previously received MEDI-563.

          -  Asthma exacerbation due to acute inhalational exposure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph M. Parker, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Emergency Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital; Dept. of Emergency Medicine</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nassau Univ. Medical Center</name>
      <address>
        <city>East Meadow</city>
        <state>New York</state>
        <zip>11554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center, Dept. of Emergency Medicine</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040-1496</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Medicine Research Center- Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=18&amp;filename=MEDI-563_CP-186_Protocol_Redacted_16Dec2014.pdf</url>
    <description>MEDI-563_CP-186_Protocol_Redacted_16Dec2014</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <disposition_first_submitted>July 14, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 14, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 18, 2016</disposition_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benralizumab</keyword>
  <keyword>MEDI-563</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

